RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CymaBay Therapeutics Stock

CymaBay Therapeutics ROE 2024

CymaBay Therapeutics ROE

-0.36

Ticker

CBAY

ISIN

US23257D1037

WKN

A116DD

In 2024, CymaBay Therapeutics's return on equity (ROE) was -0.36, a -87.69% increase from the -2.93 ROE in the previous year.

CymaBay Therapeutics Aktienanalyse

What does CymaBay Therapeutics do?

Cymabay Therapeutics Inc. is a biopharmaceutical company based in Newark, California. It was founded in 1988 by eight American scientists with a common goal of discovering and developing novel therapies for the treatment of serious diseases such as metabolic disorders, autoimmune diseases, and cancer. The company focuses on the regulation of bile acids and has specialized in three main areas: metabolic disorders, autoimmune diseases, and oncology. In the field of metabolic disorders, Cymabay Therapeutics has developed two important products: Arhalofenate and Seladelpar. Arhalofenate blocks the activation of the PPARy receptor, reducing insulin resistance, while Seladelpar activates the PPARd receptor, leading to increased fat burning and improved metabolism. In the field of autoimmune diseases, the company has developed a promising drug called MBX-2982, which targets the GPR119 receptor involved in insulin and glucose regulation. In oncology, Cymabay Therapeutics has developed a SIK2 inhibitor, which inhibits an enzyme necessary for tumor cell growth. The company collaborates with industry partners and public research institutions, holds over 200 patents, and aims to expand its potential. It conducts clinical trials and works with universities and public institutions to exchange technologies and knowledge. Cymabay Therapeutics strives to market its drugs globally and has established strategic partnerships in Europe and Asia. Overall, the company is a leader in discovering and developing novel drugs based on bile acids, with a diverse portfolio aimed at treating rare and serious diseases. CymaBay Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding CymaBay Therapeutics's Return on Equity (ROE)

CymaBay Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing CymaBay Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

CymaBay Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in CymaBay Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about CymaBay Therapeutics stock

What is the ROE (Return on Equity) of CymaBay Therapeutics this year?

The ROE of CymaBay Therapeutics this year is -0.36 undefined.

How has the Return on Equity (ROE) of CymaBay Therapeutics developed compared to the previous year?

The ROE of CymaBay Therapeutics has increased by -87.69% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of CymaBay Therapeutics?

A high ROE indicates that CymaBay Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of CymaBay Therapeutics?

A low ROE can indicate that CymaBay Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of CymaBay Therapeutics affect the company?

A change in ROE (Return on Equity) of CymaBay Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of CymaBay Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of CymaBay Therapeutics?

Some factors that can influence CymaBay Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does CymaBay Therapeutics pay?

Over the past 12 months, CymaBay Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CymaBay Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of CymaBay Therapeutics?

The current dividend yield of CymaBay Therapeutics is .

When does CymaBay Therapeutics pay dividends?

CymaBay Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CymaBay Therapeutics?

CymaBay Therapeutics paid dividends every year for the past 0 years.

What is the dividend of CymaBay Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CymaBay Therapeutics located?

CymaBay Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von CymaBay Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CymaBay Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did CymaBay Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of CymaBay Therapeutics in the year 2023?

In the year 2023, CymaBay Therapeutics distributed 0 USD as dividends.

In which currency does CymaBay Therapeutics pay out the dividend?

The dividends of CymaBay Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CymaBay Therapeutics

Our stock analysis for CymaBay Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CymaBay Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.